Form 4: Provectus CEO Converts Debt to Equity, Boosts Stake

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Preferred Stock, increasing his equity stake.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a change in his beneficial ownership.
• On September 30, 2025, an 8% unsecured convertible promissory note, with a principal amount of $175,000, was converted.
• The conversion resulted in Pershing acquiring 66,052 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Preferred Stock is scheduled for automatic conversion into common stock on June 20, 2026, unless converted earlier.
• Following this transaction, Pershing beneficially owns 66,052 shares of Series D-1 Convertible Preferred Stock and 2,484,499 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: The conversion of debt to equity by a key insider is generally viewed as a moderately positive signal, indicating confidence in the company's future, despite the potential for future dilution from the preferred stock conversion.

Positives

• The conversion of a promissory note into equity by a CEO and Director can signal management's continued confidence in the company's long-term prospects.
• The transaction reduces the company's debt obligations by converting a note into equity.

Negatives

• The future conversion of Series D-1 Preferred Stock into common stock will lead to dilution for existing common shareholders.

Risks

• Future dilution of common stock value due to the potential conversion of 66,052 shares of Series D-1 Convertible Preferred Stock into 660,520 shares of common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Conversion of an 8% unsecured convertible promissory note held by Edward Pershing, the CEO and Director, into Series D-1 Convertible Preferred Stock. This constitutes a transaction between the company and a key insider.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock value upon the conversion of Series D-1 Preferred Stock into common stock.

Next Steps

• Automatic conversion of the Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026, unless converted earlier by the holder.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Form 4, Insider Transaction, Convertible Note, Preferred Stock, Equity Conversion, CEO, Director, SEC Filing